ABBOTT’S PROCLAIM™ DRG SYSTEM OFFERS EXPANDED MRI ACCESS FOR PEOPLE SUFFERING FROM CHRONIC PAIN

Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labelling for its dorsal root ganglion (DRG) stimulation therapy, the Proclaim™ DRG neurostimulation system, which allows patients to receive full-body MRI scans while implanted with the device. The Proclaim DRG neurostimulation system is the only FDA-approved DRG technology, providing targeted relief for people with complex regional pain syndrome (CRPS) types I and II of the lower limbs by stimulating the DRG, which are clusters of nerve cells found along the spine.

CRPS is a rare and painful condition that affects about 200,000 people in the U.S. each year. Characterized by a constant or intermittent burning, stinging or tearing sensation, CRPS is more excruciating than childbirth or amputation of a limb. For people who suffer from the syndrome and struggle to control the pain, Proclaim DRG stimulation can be an effective option, as four out of five people who receive the therapy experience significant pain relief and improved quality of life.

MRI is one of the most widely used technologies to create detailed images of the inside of the body to inform diagnoses and treatment approaches for people with chronic pain. MRIs can be used to help assess the progression of CRPS. In these situations, an option like the Proclaim DRG therapy, which allows patients to receive MRI scans anywhere in the body within approved parameters, can be invaluable to the patient and radiologist.

With the expanded MRI labelling, Abbott’s Proclaim DRG neurostimulation system will offer:

Click here for U.S. important safety information on the Abbott Proclaim DRG neurostimulation system.